Back to search

Article

RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination

2024-10-18

Abstract excerpt

<h4>ABSTRACT</h4> The combination of PARP and NAMPT inhibitors (PARPi/NAMPTi) has been explored for the treatment of TNBC, Ewing Sarcoma and high grade serous carcinoma (HGSC). However, dose limiting toxicity has hampered NAMPTi in clinical trials. To maximise the therapeutic window, we set out to identify predictive genomic biomarkers. Bioinformatic analysis and screening of a panel of epithelial ovarian cancer...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a78ed6a8-8044-5f46-95e9-e1110b797578
DOI
10.1101/2024.10.15.618473
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combinationDOI 10.1101/2024.10.15.618473
Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancerSemantic proximity
Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancerSemantic proximity
Molecular/genetic therapies in ovarian cancer: future opportunities and challenges.Semantic proximity
PARP inhibitors: New partners in the therapy of cancer and inflammatory diseasesSemantic proximity
Efficacy and Mechanism of the Combination of PARP&nbsp;and CDK4/6 Inhibitors in the Treatment of Triple-negative Breast CancerSemantic proximity
Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancerSemantic proximity
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutationsSemantic proximity
Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing SarcomaSemantic proximity
Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Cancer: Systematic Review and Network Meta-AnalysisSemantic proximity
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian CancerSemantic proximity
NAMPT: A critical driver and therapeutic target for cancerSemantic proximity
Targeting inhibition of prognosis-related nicotinamide metabolism genes, including poly (ADP-ribose) polymerase 9 (PARP-9) attenuates glioma progressionSemantic proximity
Select a neighboring publication to make it the new centre.